MX2019002057A - Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. - Google Patents

Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Info

Publication number
MX2019002057A
MX2019002057A MX2019002057A MX2019002057A MX2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A
Authority
MX
Mexico
Prior art keywords
solid forms
cenicriviroc mesylate
processes
cenicriviroc
mesylate
Prior art date
Application number
MX2019002057A
Other languages
English (en)
Spanish (es)
Inventor
Ian Cooper Martin
Phiasivongsa Pasit
Kay Sharp Emma
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2019002057A publication Critical patent/MX2019002057A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019002057A 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. MX2019002057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
MX2019002057A true MX2019002057A (es) 2019-11-18

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002057A MX2019002057A (es) 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Country Status (13)

Country Link
US (1) US10301287B2 (enExample)
EP (1) EP3506896A4 (enExample)
JP (2) JP2019526628A (enExample)
KR (1) KR20190057066A (enExample)
CN (1) CN110167550A (enExample)
AU (1) AU2017321594A1 (enExample)
BR (1) BR112019003987A2 (enExample)
CA (1) CA3034606A1 (enExample)
MX (1) MX2019002057A (enExample)
RU (1) RU2019109019A (enExample)
SG (1) SG11201901438VA (enExample)
TW (1) TW201823235A (enExample)
WO (1) WO2018045043A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2019245518A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245517A1 (en) * 2018-06-18 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11426931B2 (en) 2018-06-19 2022-08-30 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245535A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11298876B2 (en) 2018-06-19 2022-04-12 Hewlett-Packard Development Company, L.P. Three-dimensional printing
EP3844209B1 (en) * 2018-08-31 2022-06-22 Evonik Operations GmbH Process for preparing a polymer powder
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
WO2021233349A1 (zh) 2020-05-22 2021-11-25 南京明德新药研发有限公司 吡啶类衍生物及其应用
WO2022177014A1 (ja) * 2021-02-22 2022-08-25 旭化成株式会社 セルロースナノファイバーを含む組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
CN1282243A (zh) 1997-12-19 2001-01-31 武田药品工业株式会社 用于拮抗ccr5的含n-酰苯胺衍生物的药物组合物
AU5301599A (en) 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
WO2001017947A1 (en) 1999-09-06 2001-03-15 Takeda Chemical Industries, Ltd. Process for the preparation of 2,3-dihydroazepine compounds
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
EP1484322A4 (en) 2002-03-12 2008-01-23 Takeda Pharmaceutical PROCESS FOR PRODUCING AN OPTICALLY ACTIVE SULFOXIDE DERIVATIVE
US20080249147A1 (en) 2004-03-24 2008-10-09 Takeda Pharmaceutical Company Limited Emulsion-Stabilized Preparation
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
PE20140406A1 (es) 2010-11-18 2014-04-16 Univ Yale Moleculas bifuncionales con actividad de reclutamiento de anticuerpos y actividad inhibitoria inicial contra el virus de la inmunodeficiencia humana
EP2846788A1 (en) * 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
UA115807C2 (uk) 2013-05-15 2017-12-26 Тобіра Терап'Ютикс, Інк. Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти)
RU2020119611A (ru) 2014-03-21 2020-06-29 Тобира Терапьютикс, Инк. Сенекривирок для лечения фиброза
US20170105969A1 (en) 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
CN112266392A (zh) * 2014-12-23 2021-01-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法

Also Published As

Publication number Publication date
BR112019003987A2 (pt) 2019-05-28
US20180057481A1 (en) 2018-03-01
CN110167550A (zh) 2019-08-23
RU2019109019A (ru) 2020-10-01
AU2017321594A1 (en) 2019-04-18
JP2019526628A (ja) 2019-09-19
RU2019109019A3 (enExample) 2021-08-23
TW201823235A (zh) 2018-07-01
JP2022137223A (ja) 2022-09-21
EP3506896A4 (en) 2020-08-26
SG11201901438VA (en) 2019-03-28
WO2018045043A1 (en) 2018-03-08
US10301287B2 (en) 2019-05-28
KR20190057066A (ko) 2019-05-27
CA3034606A1 (en) 2018-03-08
EP3506896A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MX2019001313A (es) Composiciones farmaceuticas.
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
WO2016011222A3 (en) Circular polynucleotides
WO2016011306A3 (en) Terminal modifications of polynucleotides
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX367669B (es) Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019005855A (es) Formulaciones que se pueden pulverizar.
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2014CH00840A (enExample)
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
PL3468964T3 (pl) Modulatory soce, ich kompozycje i zastosowania
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
EP4582145A3 (en) Solid state forms of ixazomib citrate
NZ721832A (en) Solid forms of tenofovir
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016083315A8 (en) Use of ox1r antagonists for the treatment of inflammatory bowel diseases